| Name | Title | Contact Details |
|---|---|---|
Andreas Busch |
Chief Innovation Officer | Profile |
Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics.
ATH's sales and technology groups build custom wireless turn-key technology solutions that relate to specific customer body motion measurement needs and market opportunities. ATH's vision is to commercialize it's patent portfolio and lead the industry in distributed wireless bioMotion technology and data capture processes. Founded in 2005, Applied Technology Holdings Inc., is a hardware and software maker specializing in wireless bioMotion monitoring systems for medical, sports, gaming, military and aviation applications. ATH's subsidiaries are experts in supporting the solution provider platforms for easy integration into the target markets. Other ATH companies participate in the Sports, Medical, Gaming, Aviation, and Military market opportunities and segments.
Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.